Cargando…

Editorial: The First Monoclonal Antibody Vaccine to Prevent Malaria Heralds a New Era of Malaria Vaccines to the Plasmodium falciparum Circumsporozoite Protein (PfCSP)

Malaria affects more than 3 billion people in 95 countries, with an estimated mortality rate of 400,000 per year. The female Anopheles spp mosquito most commonly transmits malaria, and the main burden of disease is due to Plasmodium falciparum. The most abundant antigen on the sporozoite surface is...

Descripción completa

Detalles Bibliográficos
Autor principal:	Parums, Dinah V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447852/ https://www.ncbi.nlm.nih.gov/pubmed/34511592 http://dx.doi.org/10.12659/MSM.934676

Ejemplares similares

mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
por: Hayashi, Clifford T. H., et al.
Publicado: (2022)

Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection
por: Scally, Stephen W., et al.
Publicado: (2018)

Author Correction: mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
por: Hayashi, Clifford T. H., et al.
Publicado: (2023)

Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model
por: Ludwig, Julia, et al.
Publicado: (2023)

Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice
por: Mallory, Katherine L., et al.
Publicado: (2021)

Structural basis of epitope selectivity and potent protection from malaria by PfCSP antibody L9
por: Martin, Gregory M., et al.
Publicado: (2023)

In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP)
por: Livingstone, Merricka C., et al.
Publicado: (2021)

Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection
por: Martin, Gregory M., et al.
Publicado: (2023)

Author Correction: Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model
por: Ludwig, Julia, et al.
Publicado: (2023)

Humoral Immune Responses to P. falciparum Circumsporozoite Protein (Pfcsp) Induced by the RTS, S Vaccine – Current Update
por: Ngulube, Peter
Publicado: (2023)

Malaria vaccine peptide Plasmodium falciparum circumsporozoite protein gene cloning in vaccinia virus
Publicado: (1989)

Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy
por: KC, Natasha, et al.
Publicado: (2022)

The Synthetic Plasmodium falciparum Circumsporozoite Peptide PfCS102 as a Malaria Vaccine Candidate: A Randomized Controlled Phase I Trial
por: Audran, Régine, et al.
Publicado: (2009)

Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax
Publicado: (1982)

Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines
por: Richie, Thomas L., et al.
Publicado: (2015)

Genetic Variation in the Plasmodium falciparum Circumsporozoite Protein in India and Its Relevance to RTS,S Malaria Vaccine
por: Zeeshan, Mohammad, et al.
Publicado: (2012)

Assessment of genetic diversity of Plasmodium falciparum circumsporozoite protein in Sudan: the RTS,S leading malaria vaccine candidate
por: Mohamed, Nouh Saad, et al.
Publicado: (2021)

Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein
por: Wang, Lawrence T., et al.
Publicado: (2021)

Monoclonal Antibodies against Plasmodium falciparum Circumsporozoite Protein
por: Zhang, Min, et al.
Publicado: (2017)

Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030
por: Parums, Dinah V.
Publicado: (2023)

Generation of a Genetically Modified Chimeric Plasmodium falciparum Parasite Expressing Plasmodium vivax Circumsporozoite Protein for Malaria Vaccine Development
por: Miyazaki, Yukiko, et al.
Publicado: (2020)

Variation in the Circumsporozoite Protein of Plasmodium falciparum: Vaccine Development Implications
por: Gandhi, Kavita, et al.
Publicado: (2014)

Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2021)

A human monoclonal antibody prevents malaria infection and defines a new site of vulnerability on Plasmodium falciparum circumsporozoite protein
por: Kisalu, Neville K., et al.
Publicado: (2018)

A Full-Length Plasmodium falciparum Recombinant Circumsporozoite Protein Expressed by Pseudomonas fluorescens Platform as a Malaria Vaccine Candidate
por: Noe, Amy R., et al.
Publicado: (2014)

Needle-free, spirulina-produced Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice
por: Saveria, Tracy, et al.
Publicado: (2022)

Effect of malaria transmission reduction by insecticide-treated bed nets (ITNs) on the genetic diversity of Plasmodium falciparum merozoite surface protein (MSP-1) and circumsporozoite (CSP) in western Kenya
por: Kariuki, Simon K, et al.
Publicado: (2013)

Correction: Variation in the Circumsporozoite Protein of Plasmodium falciparum: Vaccine Development Implications
por: Gandhi, Kavita, et al.
Publicado: (2016)

Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)
por: Sedegah, Martha, et al.
Publicado: (2013)

Cerebral Plasmodium falciparum malaria: The role of PfEMP1 in its pathogenesis and immunity, and PfEMP1‐based vaccines to prevent it
por: Jensen, Anja Ramstedt, et al.
Publicado: (2019)

Production of polypeptide for vaccine against malaria by cultivation of Escherichia coli transformed with vector coding for repeat unit circumsporozoite protein of Plasmodium falciparum
Publicado: (1987)

Expanding the Malaria Antibody Toolkit: Development and Characterisation of Plasmodium falciparum RH5, CyRPA, and CSP Recombinant Human Monoclonal Antibodies
por: Nacer, Adéla, et al.
Publicado: (2022)

Circumsporozoite Surface Protein-based malaria vaccines: a review
por: de Almeida, Maria Edilene Martins, et al.
Publicado: (2021)

Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein
por: Marques, Rodolfo F., et al.
Publicado: (2020)

Initial Characterization of the Pf-Int Recombinase from the Malaria Parasite Plasmodium falciparum
por: Ghorbal, Mehdi, et al.
Publicado: (2012)

PfMAP-2 is essential for male gametogenesis in the malaria parasite Plasmodium falciparum
por: Hitz, Eva, et al.
Publicado: (2020)

Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein
por: Oyen, David, et al.
Publicado: (2020)

Engineered DNA-encoded monoclonal antibodies targeting Plasmodium falciparum circumsporozoite protein confer single dose protection in a murine malaria challenge model
por: Tursi, Nicholas J., et al.
Publicado: (2022)

The Development of Whole Sporozoite Vaccines for Plasmodium falciparum Malaria
por: Itsara, Leslie S., et al.
Publicado: (2018)

Editorial: mRNA Vaccines and Immunotherapy in Oncology: A New Era for Personalized Medicine
por: Parums, Dinah V.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qkpuj2auu5n87vd4mgpd9is5j6